CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance

CorMedix Inc.

Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.
DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.
Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.
Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.
Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.